Eli Lilly and Co. (LLY)
Posted: Tue Jan 07, 2025 7:55 am
Aside from its weight-loss and diabetes treatments, Eli Lilly and Co. (LLY) has more than 100 drugs in its pipeline. And its efforts, coupled with robust demand for its treatments, keep adding to the company’s top and bottom lines.Most recently, in September 2024, Lilly received FDA approval for Ebgylss, the company’s treatment for moderate to severe atopic dermatitis, or eczema. The treatment was approved for adults and children 12 and up who haven’t been able to control the skin disease with topical treatments.Lilly is experimenting with using generative AI to create molecules for drug discovery.
Early stages but promises to do in five minutes what would normally take researchers an entire year in a traditional lab setting.Partnership with OpenAI in order to utilize that company’s generative AI to develop antimicrobials for the treatment of drug-related pathogens. Partnership with OpenAI illustrates Lilly’s “commitment to addressing significant health challenges experienced by people around the world.”Analysts are calling for earnings of $13.43 per share and revenue of $46.22 billion for the current fiscal year.
Early stages but promises to do in five minutes what would normally take researchers an entire year in a traditional lab setting.Partnership with OpenAI in order to utilize that company’s generative AI to develop antimicrobials for the treatment of drug-related pathogens. Partnership with OpenAI illustrates Lilly’s “commitment to addressing significant health challenges experienced by people around the world.”Analysts are calling for earnings of $13.43 per share and revenue of $46.22 billion for the current fiscal year.